Previously we reported on a patient who underwent an adjuvant chemotherapy because of spuriously increased alpha-fetoprotein (AFP) values (1). Comparison of different test systems revealed that the values in a one-step homologous monoclonal assay were falsely increased, whereas with polyclonal assays all results were negative. The high AFP concentrations of the monoclonal assay could not be abolished by including nonimmune serum. The factor that was responsible for the false increase could be purified and was identified as an IgG molecule (2). The results implicate the existence of a heterophilic antibody, forming a bridge between the two mouse antibodies in the test system. This phenomenon is sufficiently known and can result in errors in analyte quantification in any technique involving antigen binding toreagent antibody (for a review, see 3). Usually these interferences are potentially serious pitfalls and lead to a great deal of unnecessary follow-up testing, including invasive procedures. A remarkable fact in the present case is that the patient was not treated with mouse antibodies, neither for diagnostic nor for therapeutic purposes, and that at his work he has no contact with animals whatsoever.
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To the Editor:
Previously we reported on a patient who underwent an adjuvant chemotherapy because of spuriously increased alpha-fetoprotein (AFP) values (1). Comparison of different test systems revealed that the values in a one-step homologous monoclonal assay were falsely increased, whereas with polyclonal assays all results were negative. The high AFP concentrations of the monoclonal assay could not be abolished by including nonimmune serum. The factor that was responsible for the false increase could be purified and was identified as an IgG molecule (2). The results implicate the existence of a heterophilic antibody, forming a bridge between the two mouse antibodies in the test system. This phenomenon is sufficiently known and can result in errors in analyte quantification in any technique involving antigen binding toreagent antibody (for a review, see 3). Usually these interferences are potentially serious pitfalls and lead to a great deal of unnecessary follow-up testing, including invasive procedures. A remarkable fact in the present case is that the patient was not treated with mouse antibodies, neither for diagnostic nor for therapeutic purposes, and that at his work he has no contact with animals whatsoever.
That is why the etiology for the formation of the heterophilic antibody remained unsolved so far.
To obtain clues pertaining to the putative mechanism of its origin, we analyzed all drug preparations that the patient had taken other than those used in the chemotherapy.
Altogether To re-establish the link to the AlP kit and that to the mouse antibodies, we carried out competitive irihibition experiments with all preparations containing high-molecular-mass protein. Cross reaction of the heterophilic antibody between a preparation and the mouse IgG should remove the false positivity in the monoclonal AFP kit. The patient's serum was mixed with all preparations in different dilutions, all adjusted to the same protein concentration. After pre-incubation, we monitored the titer of the mixtures by measuring the inhibition effect in the monoclonal AlP kit. The undiluted Wobenzym solution almost completely inhibited the AFP. Increasing dilution We conclude that the patient was unintentionally immunized with the preparation Wobenzym.
The repeated antigen challenge provoked heterophilic antibodies cross-reacting with mouse IgG. This conclusion is supported by the time of taking the preparation and the following course of AFP values, which reverted to normal without any further therapy ( Figure  1) . In case of uncertain test results, especially in mouse monoclonal "sandwich" systems, doctors should pay attention to whether patients have taken preparations of animal origin.
